CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company focused on developing novel antiviral therapeutics, is set to present at the virtual Investor Summit Microcap Forum on August 20, 2024. The event, themed around 50 micro-cap companies with catalysts or strong market performance, offers a platform for CoCrystal's management to showcase their company overview at 9:00 a.m. ET.
The presentation will highlight CoCrystal's work in targeting the replication process of influenza viruses, coronaviruses, and noroviruses. Investors will have the opportunity to engage in live Q&A sessions and schedule one-on-one meetings with the management team throughout the day. This event provides a valuable opportunity for qualified investors to gain insights into CoCrystal's progress and potential in the antiviral therapeutics market.
CoCrystal Pharma (NASDAQ:COCP), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di nuove terapie antivirali, è pronta a presentare al virtuale Investor Summit Microcap Forum il 20 agosto 2024. L'evento, che si concentra su 50 aziende micro-cap con catalizzatori o prestazioni di mercato solide, offre una piattaforma affinché il management di CoCrystal presenti una panoramica della propria azienda alle 9:00 ET.
La presentazione evidenzierà il lavoro di CoCrystal nel mirare ai processi di replicazione di virus influenzali, coronavirus e norovirus. Gli investitori avranno l'opportunità di partecipare a sessioni di domande e risposte dal vivo e programmare incontri uno a uno con il team di gestione durante la giornata. Questo evento rappresenta un'importante opportunità per investitori qualificati di acquisire informazioni sui progressi e sul potenziale di CoCrystal nel mercato delle terapie antivirali.
CoCrystal Pharma (NASDAQ:COCP), una empresa de biotecnología en etapa clínica centrada en el desarrollo de nuevas terapias antivirales, está programada para presentar en el Foro Virtual de Inversores Microcap el 20 de agosto de 2024. El evento, que tiene como tema a 50 empresas micro-cap con catalizadores o un fuerte desempeño en el mercado, ofrece una plataforma para que la dirección de CoCrystal presente su visión general de la empresa a las 9:00 a.m. ET.
La presentación destacará el trabajo de CoCrystal en la mira del proceso de replicación de virus de la influenza, coronavirus y norovirus. Los inversores tendrán la oportunidad de participar en sesiones de preguntas y respuestas en vivo y programar reuniones uno a uno con el equipo de gestión durante todo el día. Este evento proporciona una valiosa oportunidad para que los inversores calificados obtengan información sobre el progreso y el potencial de CoCrystal en el mercado de terapias antivirales.
CoCrystal Pharma (NASDAQ:COCP), 임상 단계의 신약 개발을 전문으로 하는 생명공학 회사가 2024년 8월 20일 가상 투자자 서밋 마이크로캡 포럼에 발표할 예정입니다. 이 이벤트는 촉매제나 강력한 시장 성과를 지닌 50개의 마이크로캡 기업을 주제로 하며, CoCrystal 경영진이 회사 개요를 소개하는 플랫폼을 제공합니다 오전 9시(동부 표준시).
발표에서는 인플루엔자 바이러스, 코로나바이러스 및 노로바이러스의 복제 과정 목표에 대한 CoCrystal의 작업을 강조합니다. 투자자들은 라이브 Q&A 세션에 참여하고 관리 팀과의 일대일 회의를 예약할 기회를 갖게 됩니다. 이 이벤트는 자격을 갖춘 투자자들이 CoCrystal의 진행 상황과 항바이러스 치료제 시장에서의 잠재력에 대한 통찰력을 얻을 수 있는 귀중한 기회를 제공합니다.
CoCrystal Pharma (NASDAQ:COCP), une entreprise de biotechnologie en phase clinique axée sur le développement de nouvelles thérapies antivirales, est prête à présenter lors du Forum Virtuel des Investisseurs Microcap le 20 août 2024. L'événement, axé sur 50 entreprises micro-cap avec des catalyseurs ou une forte performance sur le marché, offre une plateforme pour que la direction de CoCrystal présente un aperçu de son entreprise à 9h00 heure de l'Est.
La présentation mettra en lumière le travail de CoCrystal dans la cible des processus de réplication des virus de la grippe, des coronavirus et des norovirus. Les investisseurs auront l'occasion de participer à des sessions de questions-réponses en direct et de planifier des réunions individuelles avec l'équipe de direction tout au long de la journée. Cet événement représente une précieuse opportunité pour les investisseurs qualifiés d'obtenir des informations sur les progrès et le potentiel de CoCrystal sur le marché des thérapies antivirales.
CoCrystal Pharma (NASDAQ:COCP), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung neuartiger antiviraler Therapeutika konzentriert, wird am 20. August 2024 im virtuellen Investor Summit Microcap Forum präsentieren. Die Veranstaltung mit dem Thema 50 Mikro-Cap-Unternehmen mit Katalysatoren oder starker Marktleistung bietet eine Plattform für das Management von CoCrystal, um einen Überblick über das Unternehmen zu präsentieren um 9:00 Uhr ET.
In der Präsentation wird die Arbeit von CoCrystal zur gezielten Bekämpfung des Replikationsprozesses von Influenza-Viren, Coronaviren und Noroviren hervorgehoben. Investoren haben die Möglichkeit, an Live-Q&A-Sitzungen teilzunehmen und individuelle Meetings mit dem Management-Team während des gesamten Tages zu planen. Diese Veranstaltung bietet qualifizierten Investoren eine wertvolle Gelegenheit, Einblicke in den Fortschritt und das Potenzial von CoCrystal auf dem Markt für antivirale Therapeutika zu gewinnen.
- None.
- None.
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, 2024. Management will be available for 1-on-1 meetings throughout the day.
Qualified investors can register here to view the live presentation and to ask questions.
Event: Q3 Investor Summit
Date: August 20th, 2024
Presentation Time: 9:00 a.m. ET (6:00 a.m. PT)
Location: WEBCAST LINK
The theme is 50 micro-cap companies with a catalyst and/or strong performance in the current market.
Take a deep dive with the best Investors in MicroCap
Live Q & A
Complimentary to Qualified Investors. Please REGISTER HERE.
About Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
About the Investor Summit
The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.
Contact:
Fred Rockwell
fred@investorsummitgroup.com
Investor Summit Group
SOURCE: CoCrystal Pharma
View the original press release on accesswire.com
FAQ
When is CoCrystal Pharma (COCP) presenting at the Investor Summit Microcap Forum?
What is the focus of CoCrystal Pharma's (COCP) research?
Can investors meet with CoCrystal Pharma's (COCP) management at the Investor Summit?
How can investors register for CoCrystal Pharma's (COCP) presentation at the Investor Summit?
